Cheng Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cheng Peng has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aeson Chang
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University , Parkville, Australia
1 shared publication - Alastair C. Keen
Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
1 shared publication - Andrew M. Ellisdon
Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton 3800, Victoria, Australia
1 shared publication Anh T. N. Nguyen
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences Monash University Melbourne Victoria Australia
1 shared publication- Bailey Cardwell
Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria 3004, Australia
1 shared publication - Bonan Liu
Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia
1 shared publication
Latest Publications
- 19 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (900) , eadq8279
Hox-C12 coordinates β 2 -adrenoceptor coupling to a cAMP/calcium feedforward loop to drive invasion in triple-negative breast cancer
Noradrenaline released from sympathetic neurons accelerates cancer metastasis by activating β 2 -adrenergic receptors (β 2 -adrenoceptors) on tumor cells to promote invasion. We previously showed that the β 2 -adrenoceptor promotes invasive behavior in a metastatic triple-negative breast cancer (TNBC) cell line by activating a cAMP- and calcium-mediated feedforward loop. Here, we found this mechanism in most TNBC lines that have an active β 2 -adrenoceptor. Integrated analysis of transcriptomic datasets revealed HOXC12 , which encodes a developmental homeobox transcription factor, as the most discriminating gene separating cell lines with the feedforward loop and those without it. The high expression of HOXC12 did not correlate with transcriptional changes in integral proteins associated with cAMP or calcium signaling, and immunostaining showed cytosolic localization of Hox-C12, suggesting that it played a nontranscriptional role. Knocking out HOXC12 prevented β 2 -adrenoceptor–mediated calcium signaling and invasion in cultured TNBC cells. In basal breast cancers, HOXC12 expression in tumors negatively correlated with overall and disease-free survival in patients. These findings identify a key mediator, Hox-C12, in the coordination of invasion driven by cAMP and calcium signaling in β 2 -adrenoceptor–responsive TNBC cells.
- 19 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (900) , eadq8279
Hox-C12 coordinates β 2 -adrenoceptor coupling to a cAMP/calcium feedforward loop to drive invasion in triple-negative breast cancer
Noradrenaline released from sympathetic neurons accelerates cancer metastasis by activating β 2 -adrenergic receptors (β 2 -adrenoceptors) on tumor cells to promote invasion. We previously showed that the β 2 -adrenoceptor promotes invasive behavior in a metastatic triple-negative breast cancer (TNBC) cell line by activating a cAMP- and calcium-mediated feedforward loop. Here, we found this mechanism in most TNBC lines that have an active β 2 -adrenoceptor. Integrated analysis of transcriptomic datasets revealed HOXC12 , which encodes a developmental homeobox transcription factor, as the most discriminating gene separating cell lines with the feedforward loop and those without it. The high expression of HOXC12 did not correlate with transcriptional changes in integral proteins associated with cAMP or calcium signaling, and immunostaining showed cytosolic localization of Hox-C12, suggesting that it played a nontranscriptional role. Knocking out HOXC12 prevented β 2 -adrenoceptor–mediated calcium signaling and invasion in cultured TNBC cells. In basal breast cancers, HOXC12 expression in tumors negatively correlated with overall and disease-free survival in patients. These findings identify a key mediator, Hox-C12, in the coordination of invasion driven by cAMP and calcium signaling in β 2 -adrenoceptor–responsive TNBC cells.
- Open Access
- 18 August 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (22) , 4677-4692
Biased receptor signalling and intracellular trafficking profiles of structurally distinct formylpeptide receptor 2 agonists
Background: There is increasing interest in developing FPR2 agonists (compound 43, ACT‐389949 and BMS‐986235) as potential pro‐resolving therapeutics, with ACT‐389949 and BMS‐986235 having entered phase I clinical development. FPR2 activation leads to diverse downstream outputs. ACT‐389949 was observed to cause rapid tachyphylaxis, while BMS‐986235 and compound 43 induced cardioprotective effects in preclinical models. We aim to characterise the differences in ligand‐receptor engagement and downstream signalling and trafficking bias profile.Experimental Approach: Concentration‐response curves to G protein dissociation, β‐arrestin recruitment, receptor trafficking and second messenger signalling were generated using FPR2 ligands (BMS‐986235, ACT‐389949, compound 43 and WKYMVm), in HEK293A cells. Log(τ/KA) was obtained from the operational model for bias analysis using WKYMVm as a reference ligand. Docking of FPR2 ligands into the active FPR2 cryoEM structure (PDBID: 7T6S) was performed using ICM pro software.Key Results: Bias analysis revealed that WKYMVm and ACT‐389949 shared a very similar bias profile. In comparison, BMS‐986235 and compound 43 displayed approximately 5‐ to 50‐fold bias away from β‐arrestin recruitment and trafficking pathways, while being 35‐ to 60‐fold biased towards cAMP inhibition and pERK1/2. Molecular docking predicted key amino acid interactions at the FPR2 shared between WKYMVm and ACT‐389949, but not with BMS‐986235 and compound 43.Conclusion and Implications: In vitro characterisation demonstrated that WKYMVm and ACT‐389949 differ from BMS‐986235 and compound 43 in their signalling and protein coupling profile. This observation may be explained by differences in the ligand‐receptor interactions. In vitro characterisation provided significant insights into identifying the desired bias profile for FPR2‐based pharmacotherapy.
- 18 August 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (22) , 4677-4692
Open AccessBiased receptor signalling and intracellular trafficking profiles of structurally distinct formylpeptide receptor 2 agonists
Background: There is increasing interest in developing FPR2 agonists (compound 43, ACT‐389949 and BMS‐986235) as potential pro‐resolving therapeutics, with ACT‐389949 and BMS‐986235 having entered phase I clinical development. FPR2 activation leads to diverse downstream outputs. ACT‐389949 was observed to cause rapid tachyphylaxis, while BMS‐986235 and compound 43 induced cardioprotective effects in preclinical models. We aim to characterise the differences in ligand‐receptor engagement and downstream signalling and trafficking bias profile.Experimental Approach: Concentration‐response curves to G protein dissociation, β‐arrestin recruitment, receptor trafficking and second messenger signalling were generated using FPR2 ligands (BMS‐986235, ACT‐389949, compound 43 and WKYMVm), in HEK293A cells. Log(τ/KA) was obtained from the operational model for bias analysis using WKYMVm as a reference ligand. Docking of FPR2 ligands into the active FPR2 cryoEM structure (PDBID: 7T6S) was performed using ICM pro software.Key Results: Bias analysis revealed that WKYMVm and ACT‐389949 shared a very similar bias profile. In comparison, BMS‐986235 and compound 43 displayed approximately 5‐ to 50‐fold bias away from β‐arrestin recruitment and trafficking pathways, while being 35‐ to 60‐fold biased towards cAMP inhibition and pERK1/2. Molecular docking predicted key amino acid interactions at the FPR2 shared between WKYMVm and ACT‐389949, but not with BMS‐986235 and compound 43.Conclusion and Implications: In vitro characterisation demonstrated that WKYMVm and ACT‐389949 differ from BMS‐986235 and compound 43 in their signalling and protein coupling profile. This observation may be explained by differences in the ligand‐receptor interactions. In vitro characterisation provided significant insights into identifying the desired bias profile for FPR2‐based pharmacotherapy.